Urgent need to address the Global Fund procurement cliff for TB

Activists urge the Global Fund and donors to take prompt action to address the grave risks posed to countries that are rapidly shifting from pooled procurement of TB medicines and commodities.

Read More →

Rapid shift from global to national purchase of TB drugs increases risk of stockouts and use of drugs of unknown quality

Activists urge international donors and country governments to ensure access to quality health products as domestic financing policies push programs to the edge of procurement cliff.

Read More →

Activists urge National TB Programs and treatment providers to discontinue use of harmful injectable agents in TB treatment

In a symbolic display, activists invited conference participants to discard the injectable agents and commit to rapidly scaling up access to safer, more effective medicine.

Read More →

Activists call on countries and donors to immediately scale up use of life-saving TB LAM test

Provocative distribution of yellow lemonade in urine collection cups calls attention to need for this simple, urine-based test.

Read More →

Activists interrupt TB conference opening ceremony to call on J&J to cut price of TB drug in half, to one dollar per day

Activists demand that Johnson & Johnson cut the price of bedaquiline in half, to no higher than $1 per day—$32 per person per month—double the price that researchers estimate bedaquiline could be sold for a profit.

Read More →

Médecins Sans Frontières calls on Johnson & Johnson to cut key TB drug price in half

Warns high prices of TB drugs restrict people's access to best drug-resistant TB treatment.

Read More →

Checklist of essential TB services

A new checklist from Treatment Action Group lays out simply the core elements of an adequate TB response.

Read More →

Reality Check: The Price of Bedaquiline

The "Reality Check" dispels myths that have been circulated among members of the global TB community and used to justify pricing bedaquiline out of the reach of TB programs and patients.

Read More →

Public–private mix for TB prevention and care: a roadmap

First-ever targeted roadmap outlines steps to scale-up public-private health sector engagement to end TB.

Read More →

Advocates call on Otsuka to reduce the price of delamanid

Advocates ask Otsuka to lower the price of delamanid in line with Médecins sans Frontières target regimen cost of $500.

Read More →

Page 1 of 94 · Total posts: 10

1 2 Last→